Innate Pharma
IPHA
11 hedge funds and large institutions have $483K invested in Innate Pharma in 2025 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 3 closing their positions.
206% more capital invested
Capital invested by funds: $158K → $483K (+$326K)
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
22% more funds holding
Funds holding: 9 → 11 (+2)
0.21% more ownership
Funds ownership: 0.09% → 0.3% (+0.21%)
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$179K |
| 2 |
LPC
Lion Point Capital
New York
|
+$157K |
| 3 |
OMC
Old Mission Capital
Chicago,
Illinois
|
+$54.9K |
| 4 |
Millennium Management
New York
|
+$39.2K |
| 5 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$9.14K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$39.1K |
| 2 |
Morgan Stanley
New York
|
-$13.8K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$7.43K |
| 4 |
GI
GAMMA Investing
Foster City,
California
|
-$2.33K |
| 5 |
Barclays
London,
United Kingdom
|
-$591 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Jane Street
New York
| $162K | +$179K | +92,753 | New |
|
|
LPC
2
Lion Point Capital
New York
| $142K | +$157K | +81,151 | New |
|
|
3
Morgan Stanley
New York
| $81.2K | -$13.8K | -7,170 | -13% |
|
|
OMC
4
Old Mission Capital
Chicago,
Illinois
| $49.8K | +$54.9K | +28,431 | New |
|
|
5
Millennium Management
New York
| $35.5K | +$39.2K | +20,308 | New |
|
|
6
RhumbLine Advisers
Boston,
Massachusetts
| $9.11K | +$9.14K | +4,734 | +1,007% |
|
|
GI
7
GAMMA Investing
Foster City,
California
| $1.88K | -$2.33K | -1,208 | -53% |
|
|
8
UBS Group
Zurich,
Switzerland
| $1.66K | -$7.43K | -3,850 | -80% |
|
|
FFA
9
Farther Finance Advisors
San Francisco,
California
| $18 | – | – | – |
|
|
10
Barclays
London,
United Kingdom
| $2 | -$591 | -306 | -100% |
|
|
SAG
11
SageView Advisory Group
Newport Beach,
California
| $2 | +$2 | +1 | New |
|
|
12
Citadel Advisors
Miami,
Florida
| – | -$39.1K | -20,042 | Closed |
|
13
Optiver Holding
Amsterdam,
Netherlands
| – | -$197 | -101 | Closed |
|
|
PS
14
Principal Securities
Des Moines,
Iowa
| – | -$87 | -45 | Closed |
|
IPHA Hedge Fund Activity: Q4 2025 in Review
11 of the 8,238 institutional investors tracked by Wall St. Rank reported a position in Innate Pharma (IPHA) for Q4 2025, worth a combined $483K — up 206% from $158K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new IPHA positions and 3 closed out — a net gain of 2 holders — while 1 added to existing stakes and 4 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $179K. The largest seller was Citadel Advisors, exiting entirely with an estimated $39.1K sold.
- 11 institutional investors held Innate Pharma (IPHA) as of Q4 2025, up from 9 in Q3 2025.
- Funds reported $483K of Innate Pharma stock for Q4 2025, up 206% quarter-over-quarter.
- 5 funds opened new Innate Pharma positions in Q4 2025 and 3 closed out, a net change of +2 holders.
- The largest Innate Pharma buyer in Q4 2025 was Jane Street, an estimated $179K added.
- The largest Innate Pharma seller in Q4 2025 was Citadel Advisors, an estimated $39.1K sold.
Based on aggregated 13F filings for Q4 2025.